Breast Cancer Connect
  • Saved

2yr
ASCO 2024: Pioneering Advances and Future Directions in Oncology

The ASCO 2024 conference was a landmark event, drawing 45,000 registrants and presenting over 5,000 abstracts on cutting-edge advances and research in Clinical Oncology. The emphasis on patient-centric approaches, blending high-tech and high-touch care, underscored the commitment to improving patient outcomes and experiences.

  • Saved

2yr
Vaccine-associated axillary lymphadenopathy with a focus on COVID-19 vaccines

Vaccine-associated axillary lymphadenopathy with a focus on COVID-19 vaccines

Source : https://pubmed.ncbi.nlm.nih.gov/38906159/

Axillary lymphadenopathy (LA) after COVID-19 vaccination is now known to be a common side effect. In these cases, malignancy cannot always be excluded on the basis of morphological imaging criteria.Narrative...

Vaccination history should be well documented and taken into account when evaluating suspicious LN. Biopsy of abnormal, persistent, or progressive LNs is recommended. Preoperative staging of breast cancer should not be delayed by follow-up. The risk of false-positive findings is accepted, and the suspicious LNs are histologically examined in...

  • Saved

2yr
Systematic analysis of fatty acid desaturases in breast invasive carcinoma: The prognosis, gene mutation, and tumor immune microenvironment

Systematic analysis of fatty acid desaturases in breast invasive carcinoma: The prognosis, gene mutation, and tumor immune microenvironment

Source : https://pubmed.ncbi.nlm.nih.gov/38905386/

Breast invasive carcinoma (BRCA) is one of the most common cancers in women, with its malignant progression significantly influenced by intracellular fatty acid (FA) desaturation. Stearoyl-coenzyme A desaturase (SCD) and...

This study provides an in-depth understanding of the heterogeneity and complexity of the molecular biological characteristics of SCD and FADS2 by analyzing the prognosis, mutations, and tumor immune microenvironment in BRCA. We demonstrated that SCD1 and FADS2 could be potential biomarkers to predict or diagnose aggressive breast cancer, and...

  • Saved

2yr
Final Results From the Randomized Phase III ASCENT Clinical Trial

Final Results From the Randomized Phase III ASCENT Clinical Trial

Source : https://pubmed.ncbi.nlm.nih.gov/38422473/

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or...

Trastuzumab deruxtecan (T-DXd), an HER2-targeted ADC, is approved for patients with HER2-low mBC.21 In the phase III DESTINY-Breast04 trial, T-DXd demonstrated a significant improvement in PFS and OS outcomes compared with TPC in patients with mBC with confirmed HER2-low status including in a small cohort of patients with TNBC (T-DXd, n = 40;...

  • Saved

2yr
Essential requirements for reporting radiation therapy in breast cancer clinical trials: ESTRO

Essential requirements for reporting radiation therapy in breast cancer clinical trials: ESTRO

Source : https://pubmed.ncbi.nlm.nih.gov/38122852/

The European Society for Radiotherapy and Oncology (ESTRO) has advocated the establishment of guidelines to optimise precision radiotherapy (RT) in conjunction with contemporary therapeutics for cancer care. Quality assurance in...

The European Society for Radiotherapy and Oncology (ESTRO) has advocated the establishment of guidelines to optimise precision radiotherapy (RT) in conjunction with contemporary therapeutics for cancer care. Quality assurance in RT (QART) plays a pivotal role in influencing treatment outcomes.